B-Cell-Related Neuroinflammation Across Central Nervous System Diseases: A Bibliometric and Science-Mapping Analysis, 2006-2026.
- 1Department of Physiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- 2Key Laboratory of General University of Hunan Province, Basic and Clinical Research in Major Respiratory Disease, Central South University, Changsha, Hunan, 410013, People's Republic of China.
- 3National Experimental Teaching Demonstration Center for Medical Function, Central South University, Changsha, Hunan, 410013, People's Republic of China.
Abstract
Purpose
Research on B cells in central nervous system (CNS) diseases rests on a mature multiple sclerosis (MS) literature, whereas evidence in CNS injury and neurodegeneration is still emerging. We mapped publications from 2006 to 2026 and separated bibliometric visibility from mechanistic maturity.Methods
We searched the Web of Science Core Collection (WoSCC) on August 17, 2026, for English-language records carrying the Article document-type tag and published from January 1, 2006, through August 17, 2026. Two reviewers independently screened all records, with unresolved disagreements adjudicated by a third reviewer. Publication trends, collaboration, co-citation, journal flows, citation bursts, and keyword evolution were analyzed using VOSviewer, CiteSpace, bibliometrix, R, and SCImago Graphica. Search materials, parameters, and source tables were archived.Results
After database-level limits, 2,701 records were screened; 467 (17.3%) were excluded and 2,234 (82.7%) included. The corpus had accrued 91,218 WoSCC citations. Annual output rose from 91 articles in 2016 to 231 in 2025; 173 articles from 2026 represent a partial year. The United States contributed the most articles, and the University of California, San Francisco ranked first after affiliation normalization. Co-citation and keyword analyses showed an MS/experimental autoimmune encephalomyelitis (EAE)-centered foundation built around B-cell depletion trials, meningeal pathology, diagnostic criteria, and regulatory B-cell biology. Recent bursts included anti-CD20 therapy, single-cell RNA sequencing, autoimmune encephalitis, ischemic stroke, Mendelian randomization, B-cell depletion, and Alzheimer disease.Conclusion
B-cell-related CNS research has expanded, but evidence maturity remains disease-specific. MS/EAE provides the clearest foundation. Findings in CNS injury, neurodegeneration, and candidate peripheral-CNS routes remain context-dependent and require validation by disease, anatomical compartment, B-cell state, and stage. Bibliometric prominence reveals attention, not shared causality or therapeutic efficacy.
Related
- Needle-Related Procedural Pain: An Integrated Nervous-System Framework from Tissue Mechanics to Central Processing—A Systematic Review
- Recent advances in the pharmacological effects and mechanisms of borneol and borneol-containing formulations in central nervous system diseases
- Rapid Transformation of Myelodysplastic Neoplasm to Myelodysplasia-related Acute Myeloid Leukemia with Central Nervous System Leukemia in a Young Adult
- Exploring ifosfamide-related central nervous system adverse events based on the FAERS database and clinical feature analysis of cases
- Characteristic central nervous system fingerprints and related molecular signatures in difficult-to-treat rheumatoid arthritis.
BibTeX
@article{li2026bcellrelated,
title = {{B-Cell-Related Neuroinflammation Across Central Nervous System Diseases: A Bibliometric and Science-Mapping Analysis, 2006-2026.}},
author = {Juan Li and Wen-Jia Wang and Hui Chen and Jia-Qi Sun and Wen-Jing Zhong and Cha-Xiang Guan and Yong Zhou},
journal = {Journal of inflammation research},
year = {2026},
month = oct,
doi = {10.2147/jir.s635719},
url = {https://europepmc.org/article/MED/42921194},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - B-Cell-Related Neuroinflammation Across Central Nervous System Diseases: A Bibliometric and Science-Mapping Analysis, 2006-2026.
AU - Juan Li
AU - Wen-Jia Wang
AU - Hui Chen
AU - Jia-Qi Sun
AU - Wen-Jing Zhong
AU - Cha-Xiang Guan
AU - Yong Zhou
PY - 2026
DA - 2026/10/19
JO - Journal of inflammation research
DO - 10.2147/jir.s635719
UR - https://europepmc.org/article/MED/42921194
AB - Purpose Research on B cells in central nervous system (CNS) diseases rests on a mature multiple sclerosis (MS) literature, whereas evidence in CNS injury and neurodegeneration is still emerging. We mapped publications from 2006 to 2026 and separated bibliometric visibility from mechanistic maturity.Methods We searched the Web of Science Core Collection (WoSCC) on August 17, 2026, for English-language records carrying the Article document-type tag and published from January 1, 2006, through August 17, 2026. Two reviewers independently screened all records, with unresolved disagreements adjudicated by a third reviewer. Publication trends, collaboration, co-citation, journal flows, citation bursts, and keyword evolution were analyzed using VOSviewer, CiteSpace, bibliometrix, R, and SCImago Graphica. Search materials, parameters, and source tables were archived.Results After database-level limits, 2,701 records were screened; 467 (17.3%) were excluded and 2,234 (82.7%) included. The corpus had accrued 91,218 WoSCC citations. Annual output rose from 91 articles in 2016 to 231 in 2025; 173 articles from 2026 represent a partial year. The United States contributed the most articles, and the University of California, San Francisco ranked first after affiliation normalization. Co-citation and keyword analyses showed an MS/experimental autoimmune encephalomyelitis (EAE)-centered foundation built around B-cell depletion trials, meningeal pathology, diagnostic criteria, and regulatory B-cell biology. Recent bursts included anti-CD20 therapy, single-cell RNA sequencing, autoimmune encephalitis, ischemic stroke, Mendelian randomization, B-cell depletion, and Alzheimer disease.Conclusion B-cell-related CNS research has expanded, but evidence maturity remains disease-specific. MS/EAE provides the clearest foundation. Findings in CNS injury, neurodegeneration, and candidate peripheral-CNS routes remain context-dependent and require validation by disease, anatomical compartment, B-cell state, and stage. Bibliometric prominence reveals attention, not shared causality or therapeutic efficacy.
SN - 1178-7031
ER -